FIERCEPHARMA AND FIERCEHEALTHCARE PRESENT:
CORONAVIRUS VIRTUAL SERIES
WHERE ARE WE NOW?
MAY 4–7, 2020 | FREE VIRTUAL EVENT
The editorial teams of FiercePharma and FierceHealthcare bring you another week of live virtual updates and expert panels discussing the coronavirus. We’ll do a status update about our progress so far and what challenges remain ahead.
THESE VIRTUAL EVENTS ARE FREE
MONDAY, MAY 4
Tech’s role in managing COVID-19 patients’ recovery outside the hospital and preparing for the next virus
The current situation is highlighting that virtual care in general, and remote patient monitoring specifically, are a need-to-have for the future of healthcare. Patient monitoring technologies such as wearables, AI, connected devices, and sensors, are a critical tool to manage patients outside of the clinical setting once they are discharged. These tools also can be used to monitor chronic disease patients to keep them out of already stressed hospitals. How is the current pandemic accelerating the use of patient monitoring tech? What are the challenges? What are the business opportunities? How are researchers using data from wearables like Fitbit and the Oura smart ring to identify early symptoms and better prepare the industry if the virus resurfaces in the fall, as some experts warn?
Rapid Readiness: How drug developers can maximize capacity, capabilities and expertise for Pandemic Response
The novel coronavirus COVID-19 has quickly taken over many aspects of the daily lives of people around the globe, stressing the healthcare system and putting scientists at the forefront of this pandemic. Known for expertise in preparedness for public health threats, Emergent BioSolutions has deployed its resources – capacities, capabilities and expertise – to attack this pandemic. Through collaboration with fellow innovators, our CDMO business is producing several clinical trial vaccine candidates. We have also partnered with BARDA and NIAID to develop plasma-derived therapies using our hyperimmune platform technology to treat patients with COVID-19. Join us as we investigate the progress surrounding this new challenge and discuss how pharma and biotech companies are working together to speed development, making both vaccines and treatments available to those in need.
- Pathway to tens of hundreds of millions of doses leveraging platform technologies
- Regulatory Pathway to Emergency Use Authorization
- Public and private partnerships
- Vaccine and Plasma derived therapies
Vaccines accelerate toward market: How fast and how far?
With the novel coronavirus sweeping across the globe, vaccine makers and their partners have been working full speed to help stop the pandemic. Five candidates are already in human testing, and major players such as Johnson & Johnson, Pfizer and the Gates Foundation are preparing for mass production. In all, more than 75 potential immunizations are in the works.
What’s next? In this conversation with experts and vaccine developers, we’ll assess progress so far and outline the pathway ahead, including potential pitfalls and innovative strategies for accelerating the pace to market.
TUESDAY, MAY 5
Healthcare after the ‘peak’: What happens next?
Much work has been put into flattening the curve – or reducing the “peak” number of serious illness – that's taxing our hospitals. As we approach and even finally move past those peaks, it's expected that a backlog of patients who have chronic conditions that could begin having acute problems because they haven't been seeing their doctors and how that could tax an already stressed system. How should hospitals prepare to handle this surge? How else should health systems be adapting to handle the demand for services around the country?
Leveraging Connected Health Solutions During COVID-19 and Beyond
The COVID-19 pandemic is highlighting the importance of connected health solutions, specifically remote patient monitoring and telehealth, to help address the crisis and beyond. Healthcare systems are tasked with providing immediate, quality, care to patients while also protecting employees and physicians – this is where remote healthcare can play a critical role. By extending healthcare beyond the walls of a facility, healthcare organizations can leverage remote care applications, connected and non-connected devices, two-way video and survey questions to be able to remotely triage patients based on greatest, immediate need while maintaining quality of care.
So, how and where do you start? How can you leverage remote care after COVID-19? What are the short-and long-term benefits? Join us to hear from two industry experts who have been pioneering connected health for over a decade.
Clinical Trial Challenges Amid COVID-19
To combat COVID-19, companies and their partners are pushing potential therapies and vaccines into clinical testing ASAP—but in other areas, medical research is grinding to a halt. A combination of public health worries, social distancing measures, reallocated resources and economic factors has some biopharmas hitting the brakes on enrollment. Other trials from cardiovascular and endocrine fields to neurologic disorders and cancer are only cautiously moving forward.
This dip in R&D activity could travel like an air bubble in the drug development pipeline. Some industry experts expect to see noticeable drops in the numbers of breakthrough therapies and approvals of new treatments. How far will these primary and secondary impacts of the coronavirus ripple through the coming years, and what will be their ultimate effect on public health, and the industry’s ability to serve it?
WEDNESDAY, MAY 6
Bouncing back: Payers’ role in helping the system recover from COVID-19
As we pass the peak of novel coronavirus infections, how is the healthcare system looking to ease back into normalcy, and what can health plans do to help? What are the next issues they’re planning for and what kind of cost pressures are they watching in the coming months? How can they support providers in addressing a backlog of postponed procedures? What steps are they taking now to be ready if the virus resurfaces in the fall, as some experts warn?
Lessons learned from 30+ million COVID-19 messages sent to plan members
Since the WHO declared the pandemic, mPulse has sent more than 30 million messages and IVR communications to health plan members through a variety of outreach programs. Due to the dynamic nature of the pandemic, new programs and tactics had to roll out fast to address customer and member needs. In this webinar, Rena Brar Prayaga, Director of Behavioral Science at mPulse Mobile, opens her playbook on:
- The types of programs launched to meet changing conditions and challenges
- How members engage with programs
- Strategies behind effective COVID-19 member outreach
- Addressing social isolation
mPulse Mobile’s VP of Marketing joins Rena to discuss market insights and the COVID-19 Strategic Communications Tool Kit.
Outbreak scramble: Could COVID-19 change infectious disease R&D?
We saw it with Zika and Ebola and now we’re seeing it with SARS-CoV-2. Big Pharmas and small startups alike are jumping into therapeutics development for the outbreak, repurposing old drugs, creating brand new ones and, in some cases, completely pivoting their pipelines to meet the challenge. Could infectious disease work be done differently for the next outbreak and beyond? Here, experts will discuss how the biopharma industry responds to emerging diseases and what changes it can make to be better prepared for pandemics like COVID-19. This includes measures that could be taken during “peacetime”—such as public incentives and novel partnerships—so companies are not caught flat-footed by the next outbreak, as well as efforts that can help speed the response as much as possible.
THURSDAY, MAY 7
How Life Sciences companies are rapidly responding to COVID-19 with AI and Intelligent Automation
When health crises arise, leaders and their organizations face both economic and humanitarian impacts that test infrastructure, resources, and financial models. Government, Healthcare, and Life Sciences industries must rapidly respond to these global challenges and are working at an unprecedented pace to find solutions. In our discussion, we’ll review current trends, examples from leading companies and how they are managing into the future. Intelligent automation empowers active collaboration for:
- Real-time analysis and AI-driven decision-making
- Data gathering and sharing
- Scaling of organizational capabilities
- Support for smart supply chains and business continuity plans
- Faster vaccine development to meet future recurrences
Join us for this webinar specifically dedicated to sharing current automation and Artificial Intelligence advances for the protection of businesses and human capital. As you adjust to new challenges, Robotic Process Automation (RPA) adapts with you.
Potential COVID-19 Products: Choosing the Right Path with FDA
Information is being shared by FDA in an ongoing fashion as they manage response to the current COVID-19 pandemic for ongoing and planned clinical research. If you are considering development of a product for treatment of COVID-19 or COVID-19-related indications, ensuring no time is wasted between idea and engaging FDA via the appropriate pathway with all the required information is essential. In this webinar, we’ll review the pathways you might consider, based on the development phase and overall goals for your product, and discuss the information and data necessary to help FDA expeditiously review your proposal and move it forward.